Research & Clinical Trials - Pancreas Transplant

Emory's team of transplant specialists and researchers are leading the way in transplant immunology research investigating groundbreaking strategies to stop the rejection of transplanted organs. This invaluable research is directed to help minimize the toxic side effects of daily immunosuppressant medications and achieve permanent, long-term acceptance of donor organs.

Pre-Transplant Opportunities:

BENEFIT-EXT (BMS IM103-027)

This study is for patients who are receiving their first kidney transplant from a cadaveric expanded criteria donor. The participant will receive either standard post- transplant medications or the investigational drug, Belatacept (LEA29Y) . The duration of this study is three years.

Coordinator: Elizabeth Ferry, RN

BENEFIT BMSIM103-008

This study examines treatment with an investigational drug called Belatacept as compared with cyclosporine. Patients receiving a kidney from a living or deceased donor may be eligible. The study will last three years with intravenous infusions of Belatacept once a month for those randomized to the Belatacept study arm.

Coordinator: Elizabeth Ferry, RN

CTOT-01: Non-invasive Monitoring in Kidney Transplant

This study is for patients who are receiving their first kidney transplant. The participants will give blood and urine samples before transplant and at specific times after transplant. There is a kidney biopsy done at 6 months post- transplant. If participants receive kidney from a living donor their donor has the opportunity to participate in this study as well. The duration of this study is four years.

Coordinator: Amy Lewis, RN, BSN

HIV in Solid Organ Transplant

This study is for patients who are HIV positive receiving their first or second kidney transplant. The duration of this study is five years.

Coordinator: Beth Begley, RN, BSN

PIP-01: The Impact of Chronic Immunosuppression on Protective Immunity

This study will examine whether there are unique differences in the immune system as a result of the different immunosuppression medications we currently use in kidney transplant. Blood will be drawn at 6 time points over a two year period to monitor the different cells of the immune system. Patients will be enrolled in this study at the time of transplant.

Coordinator: Cynthia Breeden

Post-Transplant Opportunities:

CTOT-02: B- cell depletion by anti-CD20 (Rituximab) in Renal Allograft Recipients who develop early de novo anti-HLA antibodies

This study is for patients who are three to twelve months post transplant. Participants are monitored for the development of HLA antibodies. If antibodies develop participants will either receive the drug rituximab, placebo, or standard treatment. The duration of the study is six years.

Coordinator: Amy Lewis, RN, BSN

ITN- Identification and Mechanistic Investigations of Tolerant Kidney Transplant Participants

This study is for patients who are at least a year out from their transplant. The purpose of this research study is to find those patients who when weaned off imunosuppression do not reject their transplanted kidney and the kidney keeps working. Blood and urine specimens will be tested from these patients for qualities that may differ from those patients who show signs of rejecting their kidney with varying levels of immunosuppression. The duration of this study is three years.

Coordinator: Amy Lewis, RN, BSN

STN-"Spare the Nephron"

This study is for patients who are between one and six months post-transplant. In this study participants either continue on the standard post transplant medications or they switch from Prograf to Rapamune. The duration of this study is two years.

Coordinator: Elizabeth Ferry, RN

If you are interested in learning more about these or other Emory Transplant Center Clinical Research projects, please call the ETC Clinical Research Program at 404-712-1114 to speak with one of our research coordinators.

Emory Transplant Center